{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:06:08Z","timestamp":1788951968702,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clbc.2026.07.028","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:59:57Z","timestamp":1784789997000},"page":"101-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epigenetic Remodeling Through GSK343-induced EZH2 Inhibition Alters SMYD2\/SMYD3 Expression and Promotes Antitumor Effects"],"prefix":"10.1016","volume":"26","author":[{"given":"Tha\u00eds Amanda Damasceno","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Vignoto","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayara","family":"Bocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fermino Sanches Lizarte","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4821-445X","authenticated-orcid":false,"given":"F\u00e1bio Morato","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.07.028_bib0001","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9605439","article-title":"Global increase in breast cancer incidence: risk factors and preventive measures","volume":"2022","author":"Kashyap","year":"2022","journal-title":"Biomed Res Int"},{"issue":"7403","key":"10.1016\/j.clbc.2026.07.028_bib0002","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.028_bib0003","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2217\/epi-2023-0016","article-title":"Epigenetics and cutaneous neoplasms: from mechanism to therapy","volume":"15","author":"Gibson","year":"2023","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.028_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41576-020-0265-5","article-title":"Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics","volume":"22","author":"Nam","year":"2021","journal-title":"Nat Rev Genet"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.028_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer: expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.028_bib0006","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","article-title":"Epigenetic mechanisms in breast cancer therapy and resistance","volume":"12","author":"Garcia-Martinez","year":"2021","journal-title":"Nat Commun"},{"issue":"14","key":"10.1016\/j.clbc.2026.07.028_bib0007","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2174\/0929867328666211108105214","article-title":"Histone modifications and their role in epigenetics of cancer","volume":"29","author":"Zaib","year":"2022","journal-title":"Curr Med Chem"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.028_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jb\/mvab007","article-title":"Targeting EZH2 as cancer therapy","volume":"170","author":"Hanaki","year":"2021","journal-title":"J Biochem"},{"key":"10.1016\/j.clbc.2026.07.028_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115594","article-title":"EZH2 can be used as a therapeutic agent for inhibiting endothelial dysfunction","volume":"213","author":"Sun","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.028_bib0010","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4161\/epi.24532","article-title":"Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond","volume":"8","author":"Deb","year":"2013","journal-title":"Epigenetics"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.028_bib0011","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3892\/or.2014.3322","article-title":"Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1\u03b1, refines relapse risk and predicts poor outcome for breast cancer","volume":"32","author":"Dong","year":"2014","journal-title":"Oncol Rep"},{"issue":"8039","key":"10.1016\/j.clbc.2026.07.028_bib0012","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41586-024-08031-6","article-title":"AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution","volume":"635","author":"Schade","year":"2024","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.028_bib0013","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3892\/etm.2021.9854","article-title":"EZH2 inhibitor GSK343 inhibits sepsis-induced intestinal disorders","volume":"21","author":"Yue","year":"2021","journal-title":"Exp Ther Med"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.028_bib0014","doi-asserted-by":"crossref","first-page":"7499","DOI":"10.1007\/s11033-021-06701-6","article-title":"Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications","volume":"48","author":"Rubio-Tom\u00e1s","year":"2021","journal-title":"Mol Biol Rep"},{"issue":"41","key":"10.1016\/j.clbc.2026.07.028_bib0015","doi-asserted-by":"crossref","first-page":"66398","DOI":"10.18632\/oncotarget.12012","article-title":"Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis","volume":"7","author":"Bagislar","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2026.07.028_bib0016","first-page":"1","article-title":"Clinical prognostic value of the SMYD2\/3 as new epigenetic biomarkers in solid cancer patients: a systematic review and meta-analysis","author":"Razmi","year":"2022","journal-title":"Expert Rev Mol Diagn"},{"issue":"7","key":"10.1016\/j.clbc.2026.07.028_bib0017","doi-asserted-by":"crossref","first-page":"9473","DOI":"10.1007\/s13277-016-4846-z","article-title":"Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia","volume":"37","author":"Oliveira-Santos","year":"2016","journal-title":"Tumour Biol"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.028_bib0018","first-page":"101","article-title":"Targeting EZH2 in cancer","volume":"24","author":"Kim","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2026.07.028_bib0019","article-title":"EZH2 inhibition in cancer therapy: recent advances and perspectives","volume":"114","author":"Italiano","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.028_bib0020","first-page":"1780","article-title":"Enhancer of zeste homolog 2 (EZH2) inhibitors in cancer: mechanisms and clinical applications","volume":"29","author":"Gulati","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.028_bib0021","first-page":"845","article-title":"Polycomb protein EZH2 regulates cancer cell fate decision in breast cancer","volume":"83","author":"Wu","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.028_bib0022","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41421-023-00644-x","article-title":"Cytoskeleton remodeling induced by SMYD2 methyltransferase drives breast cancer metastasis","volume":"10","author":"Casanova","year":"2024","journal-title":"Cell Discov"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.028_bib0023","doi-asserted-by":"crossref","first-page":"114174","DOI":"10.1016\/j.celrep.2024.114174","article-title":"Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer","volume":"43","author":"Blawski","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.clbc.2026.07.028_bib0024","doi-asserted-by":"crossref","first-page":"151363","DOI":"10.1016\/j.bbrc.2025.151363","article-title":"SMYD3 plays a pivotal role in mediating the epithelial-mesenchymal transition process in breast cancer","volume":"749","author":"Zhao","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.028_bib0025","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41419-025-07570-8","article-title":"Oncogenic activation of SMYD3-SHCBP1 promotes breast cancer development and is coupled with resistance to immune therapy","volume":"16","author":"Mo","year":"2025","journal-title":"Cell Death Dis"},{"issue":"22","key":"10.1016\/j.clbc.2026.07.028_bib0026","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.3390\/cells12222644","article-title":"SMYD3 modulates AMPK-mTOR signaling balance in cancer cell response to DNA damage","volume":"12","author":"Lepore Signorile","year":"2023","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.028_bib0027","doi-asserted-by":"crossref","first-page":"189203","DOI":"10.1016\/j.bbcan.2024.189203","article-title":"Methyltransferases in cancer drug resistance: Unlocking the potential of targeting SMYD3 to sensitize cancer cells","volume":"1879","author":"Sanese","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092600128X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092600128X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:06:27Z","timestamp":1788948387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682092600128X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S152682092600128X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.028","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic Remodeling Through GSK343-induced EZH2 Inhibition Alters SMYD2\/SMYD3 Expression and Promotes Antitumor Effects","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}